Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Polycystic Ovary Syndrome 14Breast Neoplasms 11Prostatic Neoplasms 9Obesity 7Insulin Resistance 6Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 4Colorectal Neoplasms 4Motor Activity 3Adenocarcinoma of Lung 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasms 2Menstruation Disturbances 2Lymphoma, Large B-Cell, Diffuse 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Diabetes Mellitus 2Weight Loss 1Urothelial Cancer 1Thyroid Diseases 1Thoracic Neoplasms 1Smoldering Multiple Myeloma 1Rectal Neoplasms 1Prediabetic State 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Overweight 1Ovarian, Fallopian Tube, and Primary Peritoneal Cancer 1Non-alcoholic Fatty Liver Disease 1

Interventions

Darbepoetin alfa 2piperine 1fludarabine phosphate 1ferrous sulfate 1ferric gluconate 1Whole-Body Irradiation 1Urination 1Therapeutics 1Sucrose 1Rituximab 1Phenytoin 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Mycophenolic Acid 1Morphine 1Methotrexate 1Methadone 1Metformin 1KW-2478 1Hsp90 inhibitor KU757 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Fentanyl 1Fatty Acids, Omega-3 1Epoetin Alfa 1Early Intervention, Educational 1Cyclosporine 1Curcumin 1Celecoxib 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Monoclonal Gammopathy of Undetermined Significance × Metformin × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡